Cargando…
The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide used in the treatment of type 2 diabetes. iGlarLixi has proven clinical benefits in terms of glycemia, weight control, and safety, defined by the risk of hypoglycemia. It simultaneously targets many pathophysiologic...
Autores principales: | Kwiendacz, Hanna, Nabrdalik, Katarzyna, Czupryniak, Leszek, Klupa, Tomasz, Małecki, Maciej, Myśliwiec, Małgorzata, Strojek, Krzysztof, Gumprecht, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329951/ https://www.ncbi.nlm.nih.gov/pubmed/37326901 http://dx.doi.org/10.1007/s12325-023-02567-1 |
Ejemplares similares
-
Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial
por: Giorgino, Francesco, et al.
Publicado: (2019) -
Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
por: Zisman, Ariel, et al.
Publicado: (2018) -
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
por: Blonde, Lawrence, et al.
Publicado: (2021) -
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
por: Skolnik, Neil, et al.
Publicado: (2021) -
Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study
por: Xie, Panpan, et al.
Publicado: (2023)